Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486 2497. 19. Kilpatrick RD, McAllister CJ, Kovesdy CP et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18: 293 303. 20. Glasziou PP, Irwig L, Heritier S et al. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008; 148: 656 661. 21. Takahashi O, Glasziou PP, Perera R et al. Lipid re-screening: what is the best measure and interval? Heart 2010; 96: 448 452. 22. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181 2192. 23. Palmer SC, Craig JC, Navaneethan SD et al. Benefits and harms of statin therapy for persons With chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 263 275. review C 24. Colhoun HM, Betteridge DJ, Durrington PN et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54: 810 819. 25. Tonelli M, Jose P, Curhan G et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332: 1426. 26. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238 248. 27. Fellstrom BC, Jardine AG, Schmieder RE et al. 